Editas Medicine (Seite 14)
eröffnet am 07.06.16 19:34:31 von
neuester Beitrag 05.02.24 21:13:31 von
neuester Beitrag 05.02.24 21:13:31 von
Beiträge: 596
ID: 1.233.158
ID: 1.233.158
Aufrufe heute: 0
Gesamt: 42.256
Gesamt: 42.256
Aktive User: 0
ISIN: US28106W1036 · WKN: A2AC4K · Symbol: EDIT
5,6100
USD
-4,10 %
-0,2400 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
28.02.24 · globenewswire |
21.02.24 · globenewswire |
31.01.24 · globenewswire |
08.01.24 · globenewswire |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
3.000,00 | +74.900,00 | |
0,9300 | +54,46 | |
2,3300 | +35,61 | |
2,4700 | +33,51 | |
1,9100 | +29,93 |
Wertpapier | Kurs | Perf. % |
---|---|---|
2,3000 | -20,96 | |
2,5000 | -21,88 | |
1,4300 | -24,34 | |
2,2000 | -31,25 | |
2,0900 | -40,52 |
Beitrag zu dieser Diskussion schreiben
https://www.rdmag.com/news/2018/02/new-genome-editing-method…
"New Genome-Editing Method 'Cuts Back' on Unwanted Genetic Mutations
Mon, 02/05/2018 - 10:27am
by Osaka University
Cas9 introduces a DNA double-strand break in the target gene, allowing the gene to be edited when a repair template is present. A drawback to the CRISPR/Cas9 system is that the cellular DNA repair machinery can introduce inaccuracies following a double-strand break (left panel). Nakajima et al report a new gene-editing method that avoids the formation of double-strand breaks. Cas9 nickase produces a combination of single nicks in the genome and the DNA carrying the repair template, resulting in precise and efficient gene editing (right panel). Credit: Osaka University
Deeper Insights
Building a large-scale missing persons ID SNP panel
Gene therapy is an emerging strategy to treat diseases caused by genetic abnormalities. One form of gene therapy involves the direct repair of a defective gene, using genome-editing technology such as CRISPR-Cas9. Despite its therapeutic potential, genome editing can also introduce unwanted and potentially harmful genetic errors that limit its clinical feasibility. In a study published in Genome Research, researchers centered at Osaka University report the use of a modified version of CRISPR-Cas9 that can edit genes with substantially fewer errors.
CRISPR-Cas9 works through the combined action of the Cas9 protein, which cuts DNA, and a short guiding RNA (sgRNA), which tells Cas9 where to make the cut. Together, these two molecules allow virtually any gene in the genome to be targeted for editing. The greater challenge, though, is finding a way to make specific changes to a gene once it has been targeted.
"Cas9 cleaves DNA on both of its strands, essentially splitting the target gene in two," principal investigator Shinichiro Nakada explains. "The cell tries to repair the damage by ligating the two pieces back together, but the end result is imprecise and often leaves unintended mutations."
Cells have a precise form of repair that uses donor DNA as a template to correct damage. The template acts as a molecular blueprint, allowing the cell to repair DNA with much greater accuracy. Importantly, by giving cells a different blueprint-in other words, by introducing foreign donor DNA into a cell-highly accurate edits can be made to a defective gene.
"The problem is that Cas9 cleavage is rarely repaired by the precise route," Nakada adds. "We instead used a modified Cas9 that only 'nicks' DNA in one strand, rather than cutting both strands. We discovered that when we nick both the target gene and donor DNA, we can essentially commandeer precise repair to make exact changes to the target gene."
The researchers found that the nicking technique, which they term Single Nicking in the target Gene and Donor (SNGD), greatly suppresses the rate of unintended genetic mutation compared with the conventional method. In one experiment, the standard technique made potentially-harmful errors over 90% of the time, while SNGD did so less than 5% of the time. Importantly, this precision did not impair the overall performance of the approach, which was able to efficiently achieve the desired genetic edits.
"Our study is a proof of principle that target-donor nicking can achieve accurate genome editing without DNA cleavage, which has significant implications for its use in medicine," Nakada notes. "There are many diseases for which a precise Cas9 system like this would make gene therapy more cost-effective and safer. We are very excited to see how this technique will be incorporated into the current paradigm of gene editing technologies.""
Wie gewonnen, so zerronnen...die 15% hätte sich der Kurs sparen können:
https://www.fool.com/investing/2018/01/30/what-you-should-re…
https://www.fool.com/investing/2018/01/30/what-you-should-re…
Thema hat sich ausgezockt......
Antwort auf Beitrag Nr.: 56.867.177 von belliora am 29.01.18 21:21:10Celg hat Juno gekauft einen Partner von EDIT
hat nix zu sagen, aber wird schon was laufen.
hat nix zu sagen, aber wird schon was laufen.
Ist doch gar nix gegen Crispr T......laufen doch alle nach oben, alle mit KE ? Aber warum CELG ?
Antwort auf Beitrag Nr.: 56.864.555 von question-mark am 29.01.18 17:51:48hmmmm
was kommt hier in nächster Zukunft??
ein Byout?? von CELG ?? oder ist das die Kurspflege vor einer erneuten KE???
ist schon bemerkenswert der Anstieg heute.
S.
was kommt hier in nächster Zukunft??
ein Byout?? von CELG ?? oder ist das die Kurspflege vor einer erneuten KE???
ist schon bemerkenswert der Anstieg heute.
S.
wieder der Hammer heute, Bios generell à la mode kann man nur sagen.
Antwort auf Beitrag Nr.: 56.844.103 von belliora am 26.01.18 20:05:03Jedoch mit den besten Aussichten auf maximale Gewinne, es braucht halt Zeit und Geduld, ist halt noch nicht wie derzeit beim Lithium :-)
Trotzdem die Gurke im Sektor...................
28.02.24 · globenewswire · Editas Medicine |
21.02.24 · globenewswire · Editas Medicine |
31.01.24 · globenewswire · Editas Medicine |
08.01.24 · globenewswire · Editas Medicine |
03.01.24 · globenewswire · Editas Medicine |
03.11.23 · globenewswire · Editas Medicine |
02.11.23 · globenewswire · Editas Medicine |
27.10.23 · globenewswire · Editas Medicine |
16.10.23 · globenewswire · Editas Medicine |
25.09.23 · globenewswire · Editas Medicine |